OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer

December 12th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.

Dr. Goy Discusses Single-Agent Ibrutinib in MCL

December 12th 2017

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma.

Dr. Sznol Discusses the Role of Surgery in Melanoma

December 8th 2017

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the role of surgery in the treatment of patients with melanoma.

Dr. Bouvet Discusses the Diagnosis of Thyroid Cancer

December 8th 2017

Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses the diagnosis of thyroid cancer.

Dr. Graff Discusses Sipuleucel-T in Patients With mCRPC

December 8th 2017

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer.

Dr. Zhang Discusses the KEYNOTE-564 Trial in RCC

December 8th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.

Dr. Atkins Discusses the Adjuvant Treatment of Melanoma

December 8th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

Dr. Brufsky on Implementing Pertuzumab in HER2+ Breast Cancer

December 8th 2017

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.

Dr. Daniels on Immunotherapy in Head and Neck Cancer

December 7th 2017

Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses the role of immunotherapy for patients with head and neck cancer.

Dr. Grivas on the Next Steps for Immunotherapy in Bladder Cancer

December 7th 2017

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses next steps for immunotherapy for the treatment of patients with bladder cancer.

Dr. Armstrong on Sipuleucel-T in Prostate Cancer

December 7th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses sipuleucel-T (Provenge) for patients with prostate cancer.

Dr. Hammers on the CheckMate-214 Study for RCC

December 6th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the CheckMate-214 study for patients with renal cell carcinoma (RCC).

Dr. Pant on the Third-Line Setting for Metastatic CRC

December 6th 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

Dr. Postow Discusses Combination Therapy for Melanoma

December 6th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

Dr. O'Connor Discusses Acalabrutinib in MCL

December 6th 2017

Owen O'Connor, MD, PhD, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

Dr. Barrientos Discusses Ibrutinib in Elderly Populations With CLL

December 6th 2017

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with CLL.

Dr. Jonasch on Sequencing Challenges in RCC

December 5th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses sequencing challenges facing patients with renal cell carcinoma (RCC).

Dr. Pishvaian Discusses Progress in Pancreatic Cancer

December 5th 2017

Michael Pishvaian, MD, PhD, discusses the progress that has been made in the treatment of patients with pancreatic cancer during the 2017 Ruesch Center Symposium.

Dr. Marshall Discusses the State of RAS Mutations in GI Cancers

December 5th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

Dr. McCollum Discusses Immunotherapy in CRC

December 2nd 2017

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses integrating immunotherapy into the treatment landscape of colorectal cancer (CRC).